Anthocyanins Inhibit Nuclear Factor-B 31/05/2010
Multiple effects of anthocyanins inhibiting influenza (flu) virus infectivity 31/05/2010
Cardiovascular study on Medox and cholesterol and CETP 31/05/2010
Our Medox® processing plant has continuous increased its capacity the last years A pre-process, in the making of blackcurrant anthocyanins to be used in Medox®, meeting our extreme quality standards, has been established in New Zealand. An equally important pre-process, both on blueberries and blackcurrants, has been established in France. This activity has contributed to secure the supply of raw material. Furthermore it has increased our total manufacturing capacity significantly.
New, special developed, high technology process equipment has been installed in the production line. In addition, a fully automated packing line has also been installed.
New larger and more efficient chromatographic units, speeding up our present and most challenging bottleneck, was installed during half of 2012.
Our plan for the next years is to increase the manufacturing capacity in the present facilities to surpass a production capacity of 1 million boxes of Medox® a year. During the first 12 years offering Medox®, we have managed to keep a good balance between sales and production capacity.